Casma Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

April 7, 2022

CAMBRIDGE, Mass., April 7, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to design innovative new medicines, today announced that Casma management will participate in virtual investor meetings on April 14, 2022 at the upcoming 21^st Annual Needham Virtual Healthcare Conference being held on Monday, April 11 – Thursday, April 14, 2022.

About Casma Therapeutics

Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery targets larger and more complex disease targets such as organelles, protein aggregates and large signaling complexes and directs them to the lysosome for elimination. By selectively degrading disease targets by autophagy, Casma expects to be able to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration and metabolic disorders. For more information, please visit www.casmatx.com.

Contact

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

Back to news & media

Keep reading:

News June 5, 2025
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 5, 2025 — Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, CSM-101, a first-in-class TRPML1 agonist. […]
News April 17, 2024
Casma Therapeutics to Participate at 23rd Annual Needham Virtual Healthcare Conference and at UBS Virtual Targeted Protein Degradation Day

CAMBRIDGE, Mass., April 17, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Frank Gentile, PhD, Chief Executive Officer, presented and participated in one-on-one meetings at the 23rd Annual Needham Virtual Healthcare Conference on April 5, 2024. Frank Gentile, PhD, will also attend and participate in […]